חזרה לתוצאות החיפוש

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1

מצבים רפואיים

Metastatic Hepatocellular Carcinoma · Local Advanced Hepatocellular Carcinoma · Alpha-fetoprotein (AFP)-Producing Gastric Cancer · Extragonadal Yolk Sac Tumors · Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • City of Hope Phoenix Cancer Center, Goodyear, Arizona, United States

  • City of Hope National Medical Center, Duarte, California, United States

  • City of Hope Chicago Cancer Center, Zion, Illinois, United States

  • Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States

  • Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, United States

  • Scri Oncology Partners, Nashville, Tennessee, United States

  • The University of Texas Md Anderson Cancer Center, Houston, Texas, United States

  • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Brazil

  • Hospital Da Bahia, Salvador, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto, Brazil

  • Anhui Provincial Hospital, Hefei, Anhui, China

  • Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

  • Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

  • Guangxi Medical University Cancer Hospital Wuxiang Branch, Nanning, Guangxi, China

  • The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

  • Hunan Cancer Hospital, Changsha, Hunan, China

  • The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch, Nanchang, Jiangxi, China

  • Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

  • Lishui Central Hospital, Lishui, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

  • Hopital Beaujon, Clichy, France

  • Centre Hospitalier Universitaire Nantes Hotel Dieu, Nantes, France

  • Institut Gustave Roussy, Villejuif, France

  • Irccs Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy

  • Iov Istituto Oncologico Veneto Irccs, Padova, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy

  • Irccs Humanitas Research Hospital, Rozzano, Italy

  • Kindai University Hospital, Sakai, Osaka, Japan

  • Tokyo Metropolitan Komagome Hospital, Bunkyoku, Tokyo, Japan

  • Cancer Institute Hospital of Jfcr, Kotoku, Tokyo, Japan

  • Auckland City Hospital, Auckland, New Zealand

  • Hospital Oncologico, Rio Piedras, Puerto Rico

  • Chungbuk National University Hospital, Cheongju-si, Chungcheongbukdo, South Korea

  • Cha Bundang Medical Center, Cha University, BundangGu SeongnamSi, Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea

  • Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, South Korea

  • Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, South Korea

  • Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, South Korea

  • Asan Medical Center, SongpaGu, Seoul Teugbyeolsi, South Korea

מובילי המחקר

  • Study Director

    BeOne Medicines

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)